A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials | Synapse
April 21, 2022Open Access
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.